Quantum Genesis AI Corp. (OTC: QGAI), a biotechnology company specializing in enzyme engineering, molecular modeling, and biocatalysis, issued a statement on May 19, 2026, to clarify the relationship between its research activities and those conducted by Quantumzyme LLP, a separate entity based in Bengaluru, India. The Company emphasized that Quantumzyme LLP is not a subsidiary or affiliate.
The clarification addresses prior press releases from November 5, 2025, and February 12, 2026, which referenced scientific publications related to the Company’s broader enzyme engineering field. Those publications identified researchers from Quantumzyme LLP. The Company now seeks to distinguish the two entities and provide context regarding intellectual property (IP) rights.
According to the release, scientific publications arising from research by CEO Naveen Kulkarni reflect the affiliations of contributors at the time of research. However, the Company asserts that under an Asset Purchase Agreement dated February 21, 2023, Mr. Kulkarni transferred to Quantum Genesis AI certain IP, know-how, methodologies, and related rights associated with its core enzyme engineering and biocatalysis business. A confirmatory assignment was also filed in a Current Report on Form 8-K on April 29, 2026.
The Company believes that to the extent research activities conducted by Mr. Kulkarni, whether directly or through Quantumzyme LLP, relate to its core field and are based on the transferred technology platform, such IP falls within the scope of rights transferred. The prior disclosures regarding scientific publications were made based on the Company’s ownership of the relevant IP.
This clarification matters for investors and industry observers because it delineates the boundaries of Quantum Genesis AI’s intellectual property assets. The Company’s value proposition hinges on its proprietary enzyme engineering platform, and any ambiguity about IP ownership could affect investor confidence. By formally distinguishing Quantumzyme LLP and reaffirming its control over transferred technologies, Quantum Genesis AI aims to solidify its IP position and avoid potential disputes.
For the broader biotech and AI-driven R&D sector, this case highlights the importance of clear IP attribution when research spans multiple entities. As companies increasingly use AI for enzyme design, transparent IP chains become critical for licensing, partnerships, and valuation. Quantum Genesis AI’s proactive clarification may serve as a model for other firms navigating similar multi-entity research structures.
For more information, visit Quantum Genesis AI Corp. and the Company’s profile on OTC Markets.
